koto_feja Intro Annovis Bio (NYSE:ANVS) is set to report the results of its Phase 3 trial in early-stage Parkinson’s disease (PD) in the coming weeks. The company’s lead asset, buntanetap (formerly known as posiphen), is a translational inhibitor of alpha synucelein (associated with PD), amyloid precursor protein (Alzheimer’s), TDP-43 (ALS), and other proteins associated with neurodegenerative disease (further discussion of mechanism in our initiation report). While Annovis also has an ongoing Phase 3 trial ...